Kerr, Keith M.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 2,631

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,367

Tracking the Evolution of Non–Small-Cell Lung Cancer

Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 2,349

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 2,274

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,575

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 1,298

Lung adenocarcinoma promotion by air pollutants

Hill, W., Lim, E. L., Weeden, C. E., Lee, C., Augustine, M., Chen, K., Kuan, F.-C., Marongiu, F., Evans, E. J., Moore, D. A., et al. (2023) · Nature

Air Quality and Health ImpactsCarcinogens and Genotoxicity Assessment

Cited by 808

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 592

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., et al. (2023) · Nature

Cancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

Cited by 382

Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis

Field, J. K., Vulkan, D., Davies, M. P. A., Baldwin, D. R., Brain, K. E., Devaraj, A., Eisen, T., Gosney, J., Green, B. A., Holemans, J. A., et al. (2021) · The Lancet Regional Health - Europe

Lung Cancer Diagnosis and TreatmentGlobal Cancer Incidence and Screening

Cited by 230

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Deutsch, J. S., Cimino-Mathews, A., Thompson, E., Provencio, M., Forde, P. M., Spicer, J., Girard, N., Wang, D., Anders, R. A., Gabrielson, E., et al. (2024) · Nature Medicine

Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 198

EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey

Yatabe, Y., Kerr, K. M., Utomo, A., Rajadurai, P., Tran, V. K., Du, X., Chou, T.-Y., Enriquez, M. L. D., Lee, G. K., Iqbal, J., et al. (2015) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 182

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Spicer, J., Wang, C., Tanaka, F., Saylors, G. B., Chen, K.-N., Liberman, M., Vokes, E. E., Girard, N., Lu, S., Provencio, M., et al. (2021) · Journal of Clinical Oncology

Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 139

New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center

Galateau Salle, F., Le Stang, N., Nicholson, A. G., Pissaloux, D., Churg, A., Klebe, S., Roggli, V. L., Tazelaar, H. D., Vignaud, J. M., Attanoos, R., et al. (2018) · Journal of Thoracic Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 93